Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma

Gaia Barisione, MSc; Marina Fabbi, MD, PhD; Alice Gino, MSc; Paola Queirolo, MD; Laura Orgiano, MD; Laura Spano, MD; Virginia Picasso, MD; Ulrich Pfeffer, PhD; Carlo Mosci, MD; Martine J. Jager, MD, PhD; Silvano Ferrini, MD; Rosaria Gangemi, MD

IMPORTANCE Conventional melanoma serum biomarkers (S100 and lactate dehydrogenase [LDH]) perform poorly in patients with uveal melanoma, and the search for new biomarkers is needed. A high expression of the oncoprotein c-Met in primary uveal melanoma is associated with metastatic progression, and c-Met is released as a soluble ectodomain through ADAM10- and ADAM17-mediated cleavage, suggesting a possible role as biomarker.

OBJECTIVE To determine the potential role of soluble c-Met (sc-Met) as a biomarker of uveal melanoma progression in comparison with S100 and LDH.

DESIGN, SETTING, AND PARTICIPANTS Soluble c-Met was studied in the conditioned medium of 9 uveal melanoma cell lines and in the blood serum samples of 24 mice with uveal melanoma xenografts, 57 patients with uveal melanoma (17 patients whose tumors metastasized and 40 patients whose tumors did not metastasize), and 37 healthy donors. We collected blood samples for as long as 5 years after treatment of the primary tumor. The concentration of sc-Met was measured using enzyme-linked immunosorbent assays, and the receiver operating characteristic curve was used to evaluate sensitivity and specificity in the identification of metastatic uveal melanoma. The study began on May 2, 2011, and the last samples were collected in January 2015.

MAIN OUTCOMES AND MEASURES Levels of sc-Met in uveal melanoma cell cultures and in the blood serum samples of xenotransplanted mice, of healthy donors, and of patients with uveal melanoma during follow-up.

RESULTS The conditioned medium of uveal melanoma cell lines and the blood serum samples of mice with uveal melanoma xenografts contained significant levels of sc-Met. Patients with metastatic disease had significantly higher serum levels of sc-Met (median level, 590 ng/mL [range, 246-12 856 ng/mL]) than did patients without metastatic disease (median level, 296 ng/mL [range, 201-469 ng/mL]) (P < .001) and healthy donors (median level, 285 ng/mL [range, 65-463 ng/mL]) (P < .001). Analysis of receiver operating characteristic curves for sc-Met levels in patients with nonmetastatic uveal melanoma vs patients with metastatic uveal melanoma yielded an area under the curve of 0.82 (95% CI, 0.68-0.95) (P < .001), which was superior to the areas under the curve achieved with S100 or LDH markers. Patients with progressive metastatic disease showed further increases in sc-Met level, whereas stable patients did not.

CONCLUSIONS AND RELEVANCE The present pilot study suggests that sc-Met should be further exploited as a biomarker for monitoring of uveal melanoma.

Published online June 11, 2015.

Copyright 2015 American Medical Association. All rights reserved.
Uveal melanoma is the most common primary tumor of the adult eye, with an incidence of 2 to 8 cases per million per year. Despite excellent rates of local control of the primary tumor, the survival rate of patients with uveal melanoma is not good, with a mortality rate of up to 50%. Indeed, metastatic spread to the liver, the preferential site of metastasis, is followed by death for 80% of the patients within 1 year. Although there is no standard of care for patients with metastatic disease, new targeted therapies are presently under investigation, and local therapy of the liver seems to significantly improve survival, in the presence of a limited number of metastatic lesions. However, current screening methods, including liver function tests and ultrasonography, do not identify metastases until the tumor burden is already large, with widespread development of liver metastases. Some liver function test results, an increase in serum levels of S100, tissue polypeptide-specific antigen, growth differentiation factor 15, osteopontin, melanoma inhibitory antigen, vascular endothelial growth factor, and DJ-1, and a decrease in serum levels of insulin-like growth factor have been correlated with the development of metastasis. However, there is still a need for a good biomarker that indicates the presence of early metastasis of uveal melanoma.

The hepatocyte growth factor receptor c-Met is highly expressed in patients with uveal melanoma, and it plays an important role in tumor growth and invasion. We recently reported that surface c-Met is cleaved by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 and is highly expressed in patients with uveal melanoma, and that the c-MET ectodomain is released by uveal melanoma cell lines in vitro. Moreover, both c-Met and ADAM10 messenger RNA and proteins are highly expressed in prognostically bad primary uveal melanoma. On the basis of these data, we hypothesize that during the progression of uveal melanoma to metastatic disease, an elevated level of soluble c-Met (sc-Met) may be released into the serum. Therefore, the present study analyzes the potential role of sc-Met as a biomarker of metastatic uveal melanoma.

Methods

Cell Cultures

The human uveal melanoma cell lines MEL270, OMM2.5, MEL202, MEL201, OMM1, OCM1, MEL15675, UPMM2, and UPMM3 were cultured in Roswell Park Memorial Institute 1640 medium (Gibco/Life Technologies), supplemented with 10% fetal bovine serum.

Patients and Serum Samples

Forty patients with nonmetastatic uveal melanoma, 17 patients with metastatic uveal melanoma, and 37 healthy donors were used in our study. The participants in our study provided written informed consent. All procedures were performed according to the guidelines agreed on by the ethics committee of the Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro in Genoa, Italy, and the local ethic committee of the Istituto Nazionale per la Ricerca sul Cancro in Genoa, Italy, and were performed according to the guidelines agreed on by the ethics committee of the Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro in Genoa, Italy, and the local ethic committee of the Istituto Nazionale per la Ricerca sul Cancro in Genoa, Italy, and were performed according to the guidelines agreed on by the ethics committee of the Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro in Genoa, Italy, and the local ethic committee of the Istituto Nazionale per la Ricerca sul Cancro in Genoa, Italy, and were performed according to the guidelines agreed on by the ethics committee of the Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro in Genoa, Italy.

Blood samples were kept at −37°C for 30 minutes, then centrifuged at 3000g for 20 minutes, and serum aliquots were kept at −80°C. A second serum sample was obtained during follow-up from 8 of the 40 patients with nonmetastatic uveal melanoma and from 5 of the 17 patients with metastatic uveal melanoma, based on clinical evidence of disease progression. Each patient underwent a clinical examination, a liver function test, and abdominal ultrasonography every year to determine whether the liver was metastasized. The median follow-up was 60 months (range, 6-324 months) for the patients with nonmetastatic uveal melanoma and 48.5 months (range, 10-189 months) for the patients with metastatic uveal melanoma. The median survival time of patients with metastatic uveal melanoma was 10.5 months from diagnosis of metastasis. Of the 17 patients with metastatic uveal melanoma, 13 were men and 4 were women, and the median age was 66 years. Of the 40 patients with nonmetastatic uveal melanoma, 26 were men and 14 were women, and the median age was 64.1 years. Of the 37 healthy donors, 17 were men and 20 were women, and the median age was 44 years.

At a Glance

- This pilot study explores the potential role of soluble c-Met (sc-Met) as a serum biomarker of metastatic uveal melanoma.
- Patients with metastatic uveal melanoma had significantly higher serum levels of sc-Met than did patients with nonmetastatic uveal melanoma and healthy donors.
- Analyses of receiver operating characteristic curves suggest that sc-Met may perform better than S100 and lactate dehydrogenase as a biomarker of metastatic uveal melanoma.
- These data suggest that for the follow-up of patients with uveal melanoma, sc-Met is a potential biomarker for metastatic uveal melanoma and should be further tested for the monitoring of uveal melanoma in prospective studies.

Depletion of Microvesicles From Cell Line–Conditioned Medium

Cell debris was removed by centrifugation at 3000g for 20 minutes and at 10 000g for 30 minutes. Depletion of microvesicles was obtained by further centrifugation at 100 000g for 2.5 hours.

Enzyme-Linked Immunosorbent Assay for Detection of sc-Met

The level of sc-Met was measured using the Human Total HGF R/c-MET DuoSet IC enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems), following the manufacturer’s instructions. Optical density was measured at dual wavelengths of 450 and 540 nm (400 ATC; SLT Laboratory Instruments). The intra-assay coefficient variation of the ELISA was less than 8.3%.

Statistical Analysis

The Mann-Whitney U test was performed to compare the sc-Met serum levels of the patients with metastatic uveal melanoma with the sc-Met serum levels of the patients with non-metastatic uveal melanoma. The significance level was 5%.
metastatic uveal melanoma and healthy donors. The area under the empirical receiver operating characteristic curve was calculated to study the sensitivity and specificity of serum markers. Survival curves were constructed using the Kaplan-Meier method, and the log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test were used to compare the rates of death. The survival time of patients with metastatic uveal melanoma was defined as the elapsed time between diagnosis of metastasis and death or last follow-up. Statistical analysis was performed using Prism 6 software (GraphPad Software, Inc).

**Animal Experiments**

All the mice used in our study were anesthetized with intraperitoneal injections of ketamine hydrochloride and xylazine hydrochloride. Liver metastases were obtained by injecting either 92.1 or MEL270 uveal melanoma cells (10⁶ cells in 100 μL of culture medium) that expressed the luciferase gene, under the spleen capsule of 6 NU/NU and 9 NOD/SCIDIL2Rγ null (NOG) mice. Six NOG and 3 nude tumor-free mice were used as controls. Development of metastases was monitored weekly by use of the In Vivo Imaging System. Blood samples were obtained from the tail vein of mice at the time of detection of metastasis in the liver. The experiments were performed according to the National Regulation on Animal Research Resources and approved by the institutional review board for animal experimentation at the Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Universitaria San Martino–Istituto Nazionale per la Ricerca sul Cancro in Genoa, Italy (approval identification No. IST284).

**Results**

**Sc-Met in Conditioned Medium of Uveal Melanoma Cell Lines and Serum of Mice With Uveal Melanoma Xenografts**

We have previously shown that sc-Met is detectable in the conditioned medium of uveal melanoma cell lines, owing to the
Use of Soluble c-Met as a Biomarker of Uveal Melanoma

We collected serum samples from a cohort of 40 patients with nonmetastatic uveal melanoma, 17 patients with metastatic uveal melanoma, and 37 healthy donors. The sc-Met levels were significantly higher in the serum samples of patients with metastatic uveal melanoma than in the serum samples of patients with nonmetastatic uveal melanoma (P < .001, determined by use of the Mann-Whitney test) and healthy donors (P < .001) (Figure 2A). We did not find any significant difference in sc-Met levels between the male and female participants in our study (data not shown). In addition, age did not significantly influence sc-Met levels. Indeed, if the different groups were stratified according to median age, the serum sc-Met levels showed a similar distribution in old and young participants (data not shown).

Serum Levels of sc-Met in Patients With Uveal Melanoma

We then performed an analysis of the receiver operating characteristic curves for serum sc-Met levels of patients with metastatic uveal melanoma vs patients with nonmetastatic uveal melanoma and healthy donors that yielded areas under the curve of 0.82 (95% CI, 0.68-0.95) (P < .001) and 0.83 (95% CI, 0.71-0.95) (P < .001), respectively (Figure 2B and C).
In addition, we evaluated modifications of serum levels of sc-Met in paired samples during follow-up in 8 patients with nonmetastatic uveal melanoma and 5 patients with metastatic uveal melanoma, which showed an increase in size and/or number of metastatic lesions, based on echographic or computed tomographic scans (Figure 3A and B). There was no significant change in the sc-Met serum level in the 8 patients with nonmetastatic uveal melanoma between the first and the second evaluation (mean time lapse of 31.6 months after the first test), and only one of these patients showed a 20% increase at the second evaluation (Figure 3A). On the other hand, 5 patients with metastatic uveal melanoma who developed progressive disease showed a significantly increased level of sc-Met in the second sample (P = .03, determined by use of the t test), and only one of these patients showed a 20% increase at the second evaluation (Figure 3A). Of the other 4 patients, 3 patients with nonmetastatic uveal melanoma and 1 patient with metastatic uveal melanoma showed about a 50% increase in sc-Met level (Figure 3B). Of the 17 patients with metastatic uveal melanoma, 5 were alive, 3 were lost to follow-up, and 9 had died shortly after their last follow-up. The median survival time was 9 months (range, 2-24 months) for patients with high levels (above the median value) of sc-Met and 13 months (range, 1-84 months) for patients with low levels of sc-Met. Kaplan-Meier analysis suggests that patients with sc-Met levels lower than the median value survive longer than patients with high levels of sc-Met (P = .07) (Figure 4A).

We further analyzed the relationship between sc-Met levels and survival of 12 patients with metastatic uveal melanoma with longer follow-up after sc-Met testing, stratifying these patients according to their median survival time; the levels of sc-Met in the 6 surviving patients with metastatic uveal melanoma were significantly lower than those in the 6 patients with metastatic uveal melanoma who had died (P = .04) (Figure 4B).

Serum Levels of LDH, S100, and sc-Met in Patients With Uveal Melanoma
Information on the lactate dehydrogenase (LDH) and S100 levels, evaluated within 7 days from blood sampling for sc-Met, were available for some of the patients with nonmetastatic uveal melanoma and some of the patients with metastatic uveal melanoma. The LDH levels were not significantly different between the 2 groups (P = .38), whereas significantly higher levels of sc-Met (P = .004) were detected in the patients with metastatic uveal melanoma compared with the patients with nonmetastatic uveal melanoma (Figure 5A). In contrast, serum levels of both sc-Met and S100 were significantly increased in patients with metastatic uveal melanoma (P = .001 and .03, respectively) (Figure 5B).

We then tested the predictive value of LDH, S100, and sc-Met for the detection of metastasis by an analysis of the
Use of Soluble c-Met as a Biomarker of Uveal Melanoma

Discussion

The hepatocyte growth factor receptor c-Met is a proto-oncogenic tyrosine kinase membrane receptor that works by inducing the spread of tumor cells in a broad range of tumors, including uveal melanoma. We have recently demonstrated that high levels of c-Met, ADAM10, and, to a lesser extent, ADAM17 expression in primary uveal melanoma is associated with metastatic progression. ADAM10 and ADAM17 mediate the proteolytic cleavage of c-Met and the release of sc-Met from uveal melanoma cell cultures. Indeed, the silencing of either one of these metalloproteases has reduced the level of sc-Met released.

Herein we tested the hypothesis that the level of sc-Met might be increased in the serum samples of patients with uveal melanoma that has metastasized. The present finding that the level of sc-Met is increased in the serum samples of immune-deficient mice bearing human uveal melanoma xenografts further supports this possibility. Previous reports showed the presence of sc-Met in the supernatant of several tumor cell lines (skin melanoma, mammary gland, ductal carcinoma, colorectal adenocarcinoma, renal cell carcinoma, and MG glioblastoma) and in the serum samples of different xenograft-bearing mice. Moreover, soluble Met ectodomain correlated with tumor burden in U87MG glioblastoma, NCI-H1993 non–small cell lung cancer, and H5746 human gastric cancer xenografts. In addition, high levels of circulating sc-Met were found in patients with non–small cell lung cancer and correlated with a worse outcome, while urinary sc-Met levels were significantly higher in patients with bladder carcinoma than in individuals with no evidence of cancer.

In the present study, we show that patients with metastatic uveal melanoma also have significantly higher levels of sc-Met in their serum relative to metastasis-free patients and healthy donors. Analyses of receiver operating characteristic curves suggest that sc-Met may perform better than S100 and LDH in the detection of uveal melanoma liver metastases. In fact, the areas under the curve of LDH and S100 were smaller (0.60 and 0.73, respectively) than that of soluble c-Met (0.82). Similarly, a recent report showed that the oncoprotein DJ-1/PARK7 is a suitable serum biomarker for metastatic uveal melanoma because it performed better than the liver function test. The areas under the curve reported for DJ-1 (0.86) were slightly higher than those found for sc-Met. Therefore, further prospective studies are required to test the performance of sc-Met, eventually in association with other biomarkers such as DJ-1 to determine whether it can be used for the early prediction of uveal melanoma metastases. The levels of sc-Met remained stable in sequential samples from patients whose uveal melanoma did not metastasize. Interestingly, the level increased significantly in paired serum samples obtained during the progression of existing metastases. In addition, high sc-Met levels showed a trend toward a correlation with a worse survival for these patients with metastatic uveal melanoma. It would be important to identify a biomarker that allows for the early detection of uveal melanoma metastases. However, a limit of the present study is that none of the patients with nonmetastatic uveal melanoma in our cohort developed metastases during follow-up. Therefore, we could not show evidence that sc-Met levels can be helpful to identify patients at the earliest phases of metastasis development.
Figure 5. Lactate Dehydrogenase (LDH), S100, and Soluble c-Met (sc-Met) Levels in the Serum Samples Obtained From Patients With Nonmetastatic or Metastatic Uveal Melanoma

A. Scatterplot (left) and receiver operating characteristic (ROC) analysis (right) of sc-Met and LDH levels in a subset of 34 patients with nonmetastatic uveal melanoma and 11 patients with metastatic uveal melanoma. B. Scatterplot (left) and ROC analysis (right) of sc-Met and S100 levels in 17 patients with nonmetastatic uveal melanoma and 12 patients with metastatic uveal melanoma. The horizontal line in the middle indicates the mean.
Conclusions

In conclusion, our pilot study indicates that sc-Met may be helpful for the follow-up of patients with metastatic uveal melanoma because it appeared to correlate with disease progression and worse survival. However, further prospective follow-up studies are needed to define the prognostic value of sc-Met as a biomarker in metastatic uveal melanoma.

**REFERENCES**


